This National Institute on Drug Abuse grant aims to support the discovery and development of medications for preventing and treating opioid use disorders and overdose. The grant, offered in UG3/UH3 phases, is designed to fund projects with specific milestones that lead to the advancement of safe and effective medications. Researchers can focus on preclinical or clinical studies with high impact potential to expedite the process of FDA approval. The compounds under evaluation may include small molecules or biologics, targeting various aspects of opioid use disorders and overdose. The goal is to accelerate the development of new chemical entities, formulations of existing medications, or combinations that show promise in treating opioid-related issues.
Opportunity ID: 299429
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DA-19-002 |
| Funding Opportunity Title: | Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Dec 14, 2017 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jan 01, 2020 |
| Current Closing Date for Applications: | Jan 01, 2020 |
| Archive Date: | Feb 06, 2020 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $3,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Small businesses Independent school districts County governments State governments Public housing authorities/Indian housing authorities City or township governments For profit organizations other than small businesses Public and State controlled institutions of higher education Special district governments Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid use disorders (OUD) and overdose. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat OUDs and overdose. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of OUDs such as withdrawal, craving, relapse, or overdose. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of OUDs and overdose. Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA’s drug development approval pipeline. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E | Use for due dates on or after January 25, 2018 | PKG00237052 | Jan 25, 2018 | Jan 01, 2020 | View |
Package 1
Mandatory forms
299429 RR_SF424_2_0-2.0.pdf
299429 PHS398_CoverPageSupplement_4_0-4.0.pdf
299429 RR_OtherProjectInfo_1_4-1.4.pdf
299429 PerformanceSite_2_0-2.0.pdf
299429 RR_KeyPersonExpanded_2_0-2.0.pdf
299429 RR_Budget_1_4-1.4.pdf
299429 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
299429 RR_SubawardBudget30_1_4-1.4.pdf
299429 PHS_AssignmentRequestForm_2_0-2.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
